YN320927 Cenicriviroc Mesylate 497223-28-6

Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

YN481684 NSC117079 500363-63-3

NSC117079 is a novelPHLPPinhibitor.

YN360314 PNU-120596 501925-31-1

PNU-120596 is a positive allosteric modulator of α7 nAChR with EC50 of 216 nM.

YN320846 Vilanterol 503068-34-6

Vilanterol (GW642444) is a long-actingβ2-adrenoceptor(β2-AR) agonist with 24 h activity. ThepEC50s for β2-AR,β1-AR and β3-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.

YN320847 Vilanterol trifenatate 503070-58-4

Vilanterol trifenatate is a novel inhaled long-acting beta2 adrenoceptor agonist with inherent 24-hour activity for once daily treatment of COPD and asthma.

YN440438 Caffeic acid-pYEEIE 507471-72-9

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.

YN340013 TPCA-1 507475-17-4

TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-κB pathway, exhibits 22-fold selectivity over IKK-1.

YN1710025 IRAK-1-4 Inhibitor I 509093-47-4

IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor associated kinase (IRAK) with IC50 values of 0.3 μM and 0.2 μM for IRAK-1 and IRAK-4, respectively. It displays IC50 values >10 µM in a panel...

YN321273 CCR2-RA-[R] 512177-83-2

CCR2-RA-[R] is an allosteric antagonist of theC-C chemokine receptor type 2 (CCR2)with an IC50 of 103nM.

YN361030 COG 133 514200-66-9

COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also anAChRant...

YN370338 Voclosporin 515814-01-4

Voclosporin (ISAtx-247) is acalcineurin (PP2B)(CN) inhibitor.

YN450072 (E)-SIS3 521984-48-5

SIS3, a novel specific inhibitor of Smad3, inhibits TGF-β and activin signaling by suppressing Smad3 phosphorylation without affecting the MAPK/p38, ERK, or PI3-kinase signaling pathways.

YN1710034 A2B receptor antagonist 1 531506-36-2

A2B receptor antagonist 1 is a potentA2B adenosine receptorantagonist extracted from patent WO 2009157938 A1 EXAMPLE 9B.

YN330005 PF-4878691 532959-63-0

PF-4878691 (3M-852A) is a potent, orally active, and selectiveToll-like receptor 7 (TLR7)agonist modelled to dissociate its antiviral and inflammatory activities.

YN340233 Tofacitinib citrate 540737-29-9

Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively.

YN330287 Apilimod 541550-19-0

Apilimod is a cell permeable small molecule that specifically inhibits PIKfyve with an IC50 of 14 nM in an in vitro kinase assay. It is also an inhibitor of IL-12/23 and shows no activity toward other lipid kinases a...

YN410057 QNZ 545380-34-5

QNZ (EVP4593) shows potent inhibitory activity toward both NF-κB activation and TNF-α production with IC50 of 11 nM and 7 nM in Jurkat T cells, respectively.

YN321580 Fexofenadine D6 548783-71-7

Fexofenadine D6 (MDL-16455 D6) is deuterium labeled is Fexofenadine, which is an antihistamine pharmaceutical agent.

YN481671 ERB-196 550997-55-2

ERB-196 is a nonsteroidal selectiveestrogen receptor-β(ERβ) agonist.

YN370786 Resolvin E1 552830-51-0

Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin duri...